Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Jiejun Du"'
Autor:
Julie M. Strizki, Jay A. Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G. Johnson, Jiejun Du, Patricia Carmelitano, Michelle L. Brown, Amanda Paschke, Carisa De Anda
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 12, Pp 2725-2743 (2023)
Abstract Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for outpatient treatment of mild-to-moderate COVID-19, significantly reducing the ris
Externí odkaz:
https://doaj.org/article/d0521e225c0440b48f259f56e15c4d93
Autor:
Julie M. Strizki, Jay A. Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G. Johnson, Jiejun Du, Patricia Carmelitano, Michelle L. Brown, Amanda Paschke, Carisa De Anda
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 5, Pp 1159-1160 (2024)
Externí odkaz:
https://doaj.org/article/88e4092f879442818c11a0939d8d1d66
Autor:
Ignacio Martin-Loeches, Andrew F Shorr, Marin H Kollef, Jiejun Du, Maria C Losada, Amanda Paschke, C Andrew DeRyke, Michael Wong, Erin H Jensen, Luke F Chen
Publikováno v:
Open Forum Infectious Diseases.
Background In the RESTORE-IMI 2 trial, imipenem/cilastatin/relebactam (IMI/REL) was noninferior to piperacillin/tazobactam in treating hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. This post hoc analysis was conduct
Autor:
Jason A Roberts, David P Nicolau, Ignacio Martin-Loeches, C Andrew Deryke, Maria C Losada, Jiejun Du, Munjal Patel, Matthew L Rizk, Amanda Paschke, Luke F Chen
Publikováno v:
JAC-Antimicrobial Resistance. 5
ObjectivesTo assess the relationship between renal function and efficacy/safety of imipenem/cilastatin/relebactam for the treatment of hospital-acquired/ventilator-associated pneumonia (HABP/VABP) from RESTORE-IMI 2 and determine the PTA.MethodsAdult
Autor:
Matthew G. Johnson, Julie M. Strizki, Michelle L. Brown, Hong Wan, Hala H. Shamsuddin, Moti Ramgopal, Diana F. Florescu, Pierre Delobel, Ilsiyar Khaertynova, José F. Flores, Leon F. Fouche, Shan-Chwen Chang, Angela Williams-Diaz, Jiejun Du, Jay A. Grobler, Amanda Paschke, Carisa De Anda
Publikováno v:
Infection.
Purpose Immunocompromised patients have a potentially increased risk for progression to severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis examined outcomes among immunocompromised participants in the MOVe-OUT trial. Meth
Autor:
Roberts, Jason A., Nicolau, David P., Martin-Loeches, Ignacio, Deryke, C. Andrew, Losada, Maria C., Jiejun Du, Patel, Munjal, Rizk, Matthew L., Paschke, Amanda, Chen, Luke F.
Publikováno v:
JAC-Antimicrobial Resistance; Apr2023, Vol. 5 Issue 2, p1-12, 12p
Autor:
Yoseph Caraco, Gordon E. Crofoot, Pablo Andres Moncada, Anna Nikolaevna Galustyan, Dany Badibanga Musungaie, Brendan Payne, Evgeniy Kovalchuk, Antonio Gonzalez, Michelle L. Brown, Angela Williams-Diaz, Wei Gao, Julie M. Strizki, Jay Grobler, Jiejun Du, Christopher A. Assaid, Amanda Paschke, Joan R. Butterton, Matthew G. Johnson, Carisa De Anda
Publikováno v:
NEJM Evidence. 1
Autor:
Nicholas A. Kartsonis, Antoine Roquilly, Robert W. Tipping, Luke F Chen, Aileen David-Wang, Richard G. Wunderink, Joan R. Butterton, Daniel Gonzalez, Jiejun Du, Munjal Patel, Keith S Kaye, Katherine Young, Ivan Titov, Michelle L Brown, Maria C Losada, Amanda Paschke, Helen W. Boucher, Matthew L. Rizk
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Imipenem combined with the β-lactamase inhibitor relebactam has broad antibacterial activity, including against carbapenem-resistant gram-negative pathogens. We evaluated efficacy and safety of imipenem/cilastatin/relebactam in treating h
Autor:
Angélica, Jayk Bernal, Monica M, Gomes da Silva, Dany B, Musungaie, Evgeniy, Kovalchuk, Antonio, Gonzalez, Virginia, Delos Reyes, Alejandro, Martín-Quirós, Yoseph, Caraco, Angela, Williams-Diaz, Michelle L, Brown, Jiejun, Du, Alison, Pedley, Christopher, Assaid, Julie, Strizki, Jay A, Grobler, Hala H, Shamsuddin, Robert, Tipping, Hong, Wan, Amanda, Paschke, Joan R, Butterton, Matthew G, Johnson, Carisa, De Anda, Mary Beth, Graham
Publikováno v:
The New England journal of medicine. 386(6)
New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).We condu
Autor:
Jiejun Du, Keith S Kaye, Iftihar Koksal, Angela Aggrey, Hee-Koung Joeng, Michelle L Brown, Robert W. Tipping, Thomas M. File, Johann Motsch, Viktor Stus, Ireen Khan, Joan R. Butterton, Nicholas A. Kartsonis, Amanda Paschke, Helen W. Boucher, Olexiy Lyulko, Cláudia Murta de Oliveira, Katherine Young
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections. Methods Randomized, controlled,